<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126091">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944774</url>
  </required_header>
  <id_info>
    <org_study_id>TG-873870-C-5</org_study_id>
    <nct_id>NCT01944774</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Intravenous Infusion With TG-873870</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With CAP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QPS-Qualitix</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>R&amp;G Pharma Studies Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the Efficacy, safety and pharmacokinetics of
      Intravenous Nemonoxacin Compared with Intravenous Moxifloxacin in Adult Patients with
      community-acquired pneumonia (CAP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Community-acquired Pneumonia (CAP) remains a leading cause of death in both developing and
      developed countries. In the choice of antibacterial agents used to treat CAP,
      fluoroquinolones have received considerable attention because of their wide spectrum of
      bactericidal activity. TG-873870 (Nemonoxacin), a non-fluorinated quinolone (NFQ), is a
      selective bacterial topoisomerase inhibitor.

      This study will Evaluate the clinical efficacy, microbiological efficacy and safety of
      Intravenous Nemonoxacin compared with Intravenous Moxifloxacin in adult patients with
      community-acquired pneumonia.

      Besides, the pharmacokinetics (PK) of Nemonoxacin in adult patients with CAP after
      continuous IV Infusion and the pharmacokinetic (PK)/pharmacodynamic (PD)are to be
      determined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Per subject clinical cure rate</measure>
    <time_frame>14~28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per subject microbiological cure rate</measure>
    <time_frame>14~28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per subject overall cure rate</measure>
    <time_frame>14~28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Nemonoxacin 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nemonoxacin 500mg/250mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin 650 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nemonoxacin 650 mg/325mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin 400mg/250mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemonoxacin 500 mg</intervention_name>
    <description>IV Infusion, once daily for 7~14 days</description>
    <arm_group_label>Nemonoxacin 500 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemonoxacin 650 mg</intervention_name>
    <description>IV Infusion, once daily for 7~14 days</description>
    <arm_group_label>Nemonoxacin 650 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400 mg</intervention_name>
    <description>IV Infusion, once daily for 7~14 days</description>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages between 18 and 75;

          2. Weighs between 40 ~ 100 kg, and BMI â‰¥ 18 kg/m2;

          3. Must have a clinical diagnosis of CAP

          4. Chest X-ray and /or CT scan show new or persist/progressive infiltrates

          5. Patients with PORT/PSI score II, III or IV.

          6. If female, non-lactating and at no risk or pregnancy (post-menopausal or must use
             adequate birth control)

          7. The patient is able to receive an intravenous infusion of the drug .

        Exclusion Criteria:

          1. Patients with PORT/PSI score I or VI.

          2. Severe CAP is present if a patient needs invasive mechanical ventilation or requires
             vasopressors.

          3. Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary
             tuberculosis or infection with other mycobacteria or fungi, known bronchial
             obstruction, a history of post-obstructive pneumonia, other confounding respiratory
             diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess,
             empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory
             infection (chronic obstructive pulmonary disease [COPD] is not exclusionary)

          4. Clinically significant conduction or other abnormality on 12-lead ECG, or QTc
             interval

          5. Potassium is &lt; 3.5 mmol/L

          6. Any known disease that seriously affect the immune system

          7. Active hepatitis or decompensated cirrhosis;

          8. Have used quinolones or fluoroquinolones within 14 days before enrollment

          9. Patients who are being or will be on a long-term medication of steroids
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Antibiotics, Huashan Hospital, Fundan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingyuan Zhang, PhD</last_name>
      <email>yyzhang@hsh.stn.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Yingyuan Zhang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Far eastern memorial hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Lung Cheng</last_name>
      <email>chest5415@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Shih-Lung Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 13, 2013</lastchanged_date>
  <firstreceived_date>August 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moxifloxacin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
